Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B

Hepato-Gastroenterology

Volumn 59, Issue 114, 2012, Pages 477-480

  Güzelbulut, Fatih ^a   Övünç, Ayse Oya Kurdas ^a   Çetinkaya, Züleyha Akkan ^a   Şenateş, Ebubekir ^a   Gökden, Yasemin ^a   Saltürk, Ayça Gökçen Deǧirmenci ^a   Sezikli, Mesut ^a   Özkara, Selvinaz ^a   Çetinkaya, Fuat ^a  

^a HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Chronic hepatitis B; Entecavir; Tenofovir

Indexed keywords

ENTECAVIR; TENOFOVIR; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOPSY; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84860564786     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11426     Document Type: Article

References (22)

1. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107.
2. European Association for the Study of the Liver: EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
3. Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009; 50(3):661-662.
4. Chen CJ, Yang HI, Iloeje UH; REVEAL-HBV Study Group: Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49(5 Suppl):S72-84.
5. Dienstag JL, Goldin RD, Heathcote EJ, et al.: Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124(1):105-117. (Pubitemid 36055344)
6. Llaw YF, Sung JJ, Chow WC, et al.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351(15):1521-1531.
7. Buster EH, Hansen BE, Lau GK, et al.: Factors that Predict Response of Patients With Hepatitis B eAntigen-Positive Chronic Hepatitis B to Peginterferon-Alfa. Gastroenterology 2009; 137(6):2002-2009.
8. Bonino F, Marcellin P, Lau GK, et al.: Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56(5):699-705.
9. Lai CL, Dienstag J, Schiff E, et al.: Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36(6):687-696. (Pubitemid 36337972)
10. Poordad F, Chee GM: Viral resistance in hepatitis B: prevalence and management Curr Gastroenterol Rep 2010; 12(1):62-69.
11. Chang TT, Gish RG, de Man R, et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354(10):1001-1010. (Pubitemid 43357804)
12. Lai CL, Shouval D, Lok AS, et al: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354(10):1011-1020. (Pubitemid 43357805)
13. Marcellin P, Heathcote EJ, Buti M, et al.: Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359(23):2442-2455.
14. Chang TT, Lai CL, Kew Yoon S, et al.: Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51(2):422-430.
15. Colonno RJ, Rose R, Baldick CJ, et al.: Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006; 44(6):1656-1665. (Pubitemid 44953670)
16. Snow-Lampart A, Chappell B, Curtis M, et al.: No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53(3):763-773.
17. Zhao P, Liu W, Zhao J, Guan Q: Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-na'ive Asian patients with chronic hepatitis B: a meta-analysis. Virol J 2011; 8(1):75.
18. Schiff E, Simsek H, Lee WM, et al.: Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.Am J Gastroenterol 2008; 103(11):2776-2783. Erratum in: Am J Gastroenterol 2009; 104(2):540.
19. Schiff ER, Lee SS, Chao YC, et al.: Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011; 9(3):274-276.
20. Chang TT, Liaw YF, Wu SS, et al.: Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010; 52(3):886-893.
21. Zoulim F, Perrillo R: Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48(Suppl 1):S2-19.
22. Liaw YF, Sheen IS, Lee CM, et al.: Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53(1):62-72.